Tevogen Bio Inc

Tevogen Bio highlights phase I trial data of TVGN 489, an allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes immunotherapy, published in 'Blood Advances'. Key findings include persistence of CTLs in patients and potential for treating Long COVID.

Tevogen Bio's phase I trial data of TVGN 489, an allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes immunotherapy, showed symptom improvement and faster resolution in high-risk patients, with 92% viral elimination by day +4 and 100% by day +14. The therapy was well-tolerated and did not interfere with endogenous responses. Persistence of donor-derived CTLs was noted through 6 months, suggesting potential for sustained therapeutic effects.

Tevogen Bio plans to share its $1B+ revenue potential, reflecting its unique, faster, and cost-efficient drug development model. The company’s pipeline includes treatments for SARS-CoV-2, cervical cancer, EBV-associated lymphomas, mouth and throat cancer, and multiple sclerosis. Forward-looking statements caution actual results may differ due to various risks and uncertainties.

TVGN 489 showed no dose-limiting toxicities or significant adverse events, met endpoints for viral load reduction and anti-COVID-19 responses, and all treated patients returned to baseline health within 14 days with no COVID reinfection or Long COVID observed at 6-month follow-up.